An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)

Trial Profile

An open label, multi-center, efficacy and safety study of deferasirox in iron overloaded patients with non-transfusion dependent thalassemia (THETIS)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Deferasirox (Primary)
  • Indications Iron overload
  • Focus Therapeutic Use
  • Acronyms THETIS
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 09 Jul 2016 Planned End Date changed from 1 Dec 2018 to 1 Jan 2019.
    • 09 Jul 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.
    • 08 Dec 2015 Results (n=134) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top